| Name | Ormutivimab |
|---|
| Description | Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Ormutivimab (20 IU/kg;肌肉注射;单剂量) 保护比格犬免受 RABV BD06 的致命攻击[1]。 Ormutivimab (20 IU/kg、100 IU/kg;肌注;单剂量) 保护受攻击的 Kunming 小鼠免受各种狂犬病病毒的侵害[1]。 Animal Model: Balb/c mice challenge model with rabies virus[1] Dosage: 20 IU/kg, 100 IU/kg Administration: Intramuscular injection; single dose after 4 hr after infection Result: Protected mice from rabies CVS-24 and GZ-1 isolates at a comparable rate (90%) to that of HRIG, human antirabies immune globulin. |
| References |
| No Any Chemical & Physical Properties |